'Breakthrough Alzheimer's drug' 

A new Alzheimer's drug called donanemab could be available on the NHS by 2025, the i reports, hailing it as a "breakthrough".

Researchers have found that treatment appears to slow the pace of the disease by a third, but there are some potential side effects - including brain swelling, the paper notes.

Like Leqembi and Aduhelm, donanemab is a monoclonal antibody that attacks plaque in the brain, which is made up of a protein called amyloid.

Amyloid plaques lead to the spread of another protein called tau. Both amyloid and tau proteins lead to the development of Alzheimer’s disease.